Literature DB >> 12410568

Health status and health-related quality of life associated with hemophilia.

Ronald D Barr1, Mahassen Saleh, William Furlong, John Horsman, Julia Sek, Mohan Pai, Irwin Walker.   

Abstract

The hemophilias are a group of disorders associated with a chronic burden of morbidity and early mortality. Improvements in these adverse features have been achieved by the use of clotting factor concentrates within comprehensive centers of specialized care providing home infusion programs. Offsetting effects from transfusion-transmitted hepatitis and HIV infection are in recent decline. The net impact of these changes merits assessment. To test the a priori hypotheses that increasing severity of factor VIII deficiency would be associated with an increasing burden or morbidity and that hepatitis and HIV positivity would impair health status further, a cross-sectional study of a population-based cohort was undertaken in a regional hemophilia program in Ontario, Canada. A survey was made of mild, moderate, and severe hemophiliacs over 13 years of age who self-reported their health status using a standard 15-item questionnaire. The responses were converted to levels in the Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3) health status classification systems to form multi-element vectors from which single-attribute morbidity and overall health-related quality of life utility scores were determined. The burden of morbidity was greater in hemophiliacs than in the general population and correlated with the category of disease (mild < moderate < severe). Hepatitis and HIV positivity conferred additional burdens of morbidity, which were mainly in the attributes of mobility (HUI2), ambulation (HUI3), and pain (HUI2/3), all of these differences reaching levels of statistical significance. Despite demonstrable improvements in the safety, effectiveness, and utilization of clotting factor concentrates, hemophiliacs continue to experience an important burden of morbidity. Measurement of this burden, as reported here, provides a basis for future economic evaluation of the costs and consequences of health care interventions provided to this population. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12410568     DOI: 10.1002/ajh.10191

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  19 in total

1.  Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life.

Authors:  C Rae; W Furlong; J Horsman; E Pullenayegum; C Demers; J St-Louis; D Lillicrap; R Barr
Journal:  Haemophilia       Date:  2012-09-21       Impact factor: 4.287

Review 2.  Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.

Authors:  Paolo A Cortesi; Lucia S D'Angiolella; Alessandra Lafranconi; Mariangela Micale; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

Review 3.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

4.  Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index (Haem-a-Qol) at a Brazilian blood center.

Authors:  Adriana Aparecida Ferreira; Isabel Cristina Gonçalves Leite; Maria Teresa Bustamante-Teixeira; Camila Soares Lima Corrêa; Danielle Teles da Cruz; Daniela de Oliveira Werneck Rodrigues; Monica Calil Borges Ferreira
Journal:  Rev Bras Hematol Hemoter       Date:  2013

5.  Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy.

Authors:  Giancarlo Castaman; Angiola Rocino; M Gabriella Mazzucconi; Ezio Zanon; Fabio Gagliano; Angelo C Molinari
Journal:  Blood Transfus       Date:  2015-05-14       Impact factor: 3.443

6.  Quality of life in hemophilia complicated by inhibitors.

Authors:  P Bastani; K Pourmohamadi; M Karimi
Journal:  Iran Red Crescent Med J       Date:  2012-04-01       Impact factor: 0.611

7.  Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy.

Authors:  Jennifer Quinn; Kathleen A Delaney; Wing Yen Wong; Wolfgang Miesbach; Monika Bullinger
Journal:  Patient Relat Outcome Meas       Date:  2022-07-18

8.  The effect of yoga on the quality of life in the children and adolescents with haemophilia.

Authors:  Noushin Beheshtipoor; Shahapar Bagheri; Fatemeh Hashemi; Najaf Zare; Mehran Karimi
Journal:  Int J Community Based Nurs Midwifery       Date:  2015-04

9.  Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

Authors:  Karissa Johnston; Jayson M Stoffman; Alexis T Mickle; Robert J Klaassen; Demitri Diles; Shade Olatunde; Lina Eliasson; Roxana Bahar
Journal:  Patient Prefer Adherence       Date:  2021-06-24       Impact factor: 2.711

10.  Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.

Authors:  Roberto Furlan; Sangeeta Krishnan; Jeffrey Vietri
Journal:  Patient Prefer Adherence       Date:  2015-11-23       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.